3 No-Brainer Stocks to Buy on the Latest Sell-Off

Article argues that three pullback stocks offer long-term value: ExxonMobil, Nvidia, and Vertex Pharmaceuticals. ExxonMobil highlights strong operating momentum with earnings up >$15B and cash flow up >$20B over five years, plus a 3.75% forward dividend yield and a 6.4x EV/EBITDA multiple. Nvidia is framed positively on Blackwell GPU shipments after a ~13% decline, with management calling demand “insane,” while Vertex is positioned for a rebound after a phase 2 suzetrigine miss as the FDA advanced Trikafta labeling and approved Alyftrek for cystic fibrosis, with an suzetrigine PDUFA date of Jan. 30, 2025.

Analysis

The common thread is not “cheap is good,” but where the market is mispricing path dependency. XOM only works if crude stabilizes; otherwise the dividend/buyback story is a slow offset to commodity beta, and the cleaner beneficiaries of lower oil are actually downstream consumers and aviation, not upstream producers. If energy weakness persists for 1-3 months, expect XOM to lag broader value despite optically low multiples; the falsifier is a sustained move back in WTI/Brent that re-anchors cash flow expectations.

NVDA is a different setup: the trade is less about whether demand exists and more about whether supply can convert demand into revenue without margin slippage. The second-order winners are the ecosystem names that get pulled into the AI capex cycle, but the near-term risk is digestion after hyperscaler spending gets repriced, which can compress the whole SOXX/SMH complex even if NVDA executes. Over 6-18 months the bull case survives, but over days to weeks the stock is vulnerable to any sign of export friction, customer concentration, or Blackwell ramp delays.

VRTX is the most interesting because the selloff likely embedded a binary worst case while leaving franchise durability underappreciated. The market may be missing that a trial miss in one indication does not impair the CF cash engine, and that regulatory or label success can re-rate the stock before any broader pipeline readout. That said, this is a catalyst-driven trade, not a casual long: the key false signal is either a narrow label/negative FDA action or evidence that the pain program needs materially more time, which would keep the multiple capped for months.

Key Decisions for Investors

• VRTX: Buy on weakness into the next FDA catalyst, but size via a 1-3 month call spread or staggered equity entries; favorable if the market is pricing an outright program failure, with downside limited by the core CF franchise. Falsify on a narrow/negative FDA decision or materially weaker launch commentary.
• NVDA: Stay long, but prefer pullback entries over chasing momentum; the better risk/reward is a 3-6 month horizon into Blackwell ramp commentary and hyperscaler capex updates. Use SOXX as a hedge if you want broad AI exposure without single-name supply-chain risk.
• XOM: Hold only if you already own it for income; do not add aggressively until crude stops making lower lows. If WTI stabilizes and energy equities stop underperforming, XOM becomes a cleaner carry trade; if oil breaks lower again, trim and rotate into downstream beneficiaries instead.
• Pair trade idea: long VRTX / short XBI for 1-3 months as a quality-vs-speculation expression. The thesis is that profitable biotech with durable cash flows will re-rate faster than the unprofitable biotech basket if rates stay elevated and risk appetite stays selective.